目的 探討云芝菌膠囊聯(lián)合甘草酸二銨膠囊治療病毒性肝炎的臨床療效。方法 選取2015年8月—2016年8月在恩施市中心醫(yī)院接受治療的病毒性肝炎患者86例，根據(jù)治療方案的差別分為對照組（43例）和治療組（43例）。對照組口服甘草酸二銨膠囊，3粒/次，3次/d。治療組在對照組基礎(chǔ)上口服云芝菌膠囊，3粒/次，3次/d。兩組患者均治療3個月。比較兩組患者治療前后臨床療效、肝功能、生活質(zhì)量評分和肝纖維化指標差異。結(jié)果 治療后，對照組和治療組的總有效率分別為81.40%、95.35%，兩組總有效率比較差異具有統(tǒng)計學(xué)意義（P< 0.05）。治療后，兩組血清丙氨酸氨基轉(zhuǎn)移酶（ALT）、天門冬氨酸轉(zhuǎn)氨酶（AST）和總膽紅素（TBIL）水平顯著降低，凝血酶原活動度（PTA）水平顯著升高，同組比較差異具有統(tǒng)計學(xué)意義（P< 0.05）；且治療組上述肝功能指標顯著優(yōu)于對照組（P< 0.05）。治療后，兩組患者軀體功能、心理功能、社會功能和物質(zhì)生活評分均比同組治療前明顯升高（P< 0.05）；且治療組生活質(zhì)量評分升高的更顯著（P< 0.05）。治療后，兩組患者血清透明質(zhì)酸（HA）、層黏連蛋白（LN）、Ⅲ型前膠原肽（PC-III）和Ⅳ型膠原（IV-C）均比同組治療前明顯降低（P< 0.05）；且治療組患者降低程度顯著優(yōu)于對照組（P< 0.05）。結(jié)論 云芝菌膠囊聯(lián)合甘草酸二銨膠囊治療病毒性肝炎效果顯著，可明顯改善患者生活質(zhì)量、肝功能及肝纖維化指標，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the clinical efficacy of Yunzhijun Capsules combined with Diammonium Glycyrrhizinate Capsules in treatment of viral hepatitis. Methods Patients (86 cases) with viral hepatitis in Enshi Central Hospital from August 2015 to August 2016 were divided into control (43 cases) and treatment (43 cases) groups based on different treatment. Patients in the control group were po administered with Diammonium Glycyrrhizinate Capsules, three grains/time, three times daily. Patients in the treatment group were po administered with Yunzhijun Capsules on the basis of the control group, three grains/time, three times daily. Patients in two groups were treated for three months. After treatment, the clinical efficacy, liver function, and quality of life scores, liver fibrosis indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.40% and 95.35%, respectively, and there was difference between two groups (P < 0.05). After treatment, the ALT, AST, and TBIL levels in two groups significantly decreased, but PTA level was increased, and the difference was statistically significant in the same group (P < 0.05). And these liver function indicators in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the somatic, psychological and social function, and material life score in two groups significantly increased (P < 0.05). And the quality of life scores in treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the HA, LN, PC-III and IV-C in two groups were significantly decreased (P < 0.05). And the decreased degree of these liver fibrosis indexes in treatment group was significantly better than that in the control group (P < 0.05). Conclusion Yunzhijun Capsules combined with Diammonium Glycyrrhizinate Capsules has significant effect in treatment of viral hepatitis, can significantly improve the quality of life, liver function and liver fibrosis index, which has a certain clinical application value.